MDA

As interest rates surge: flighty deposits and lending

Retrieved on: 
Friday, April 5, 2024
Neumark, Face, BCBS, Quarterly Journal of Economics, COVID-19, Cash, MRO, Intensive word form, Duration, Disclosure, The, Return, Bank statement, DFR, Research Papers in Economics, Investment, DEP, Federal, Prudential, CEMFI, Core, Synthetic control method, Interest rate risk, Journal of Political Economy, Policy, OLS, Logic, PDF, LOAN, ECB, Risk, International, Shock, Quarterly Journal, ROA, Risk management, Panetta, HHS, T2, T3, E51, Silicon Valley Bank, Common, Social science, NBER, EBA, Propensity score matching, Control, JEL, University Challenge 2013–14, Database, Rigidity, Yb, Social Science Research Network, The Journal of Finance, Bednarek, Journal, Research, Public policy, AT1, Journal of Monetary Economics, PSM, Big data, McPhail, Literature, Medical classification, Federal Reserve, Robustness, Paper, NPL, Financial economics, Deposit account, European Central Bank, Gérard Schivardi, Remuneration, Central bank, Conference, Environment, Political economy, MDA, Equation, Collateral damage, Monetary economics, Monetary policy, Kernel, Hoffmann, Website, Movement, Reproduction, Financial intermediary, Silicon, FE, Working paper, Injection, American Economic Review, Data, G21, AnaCredit, Probability, Total, Lombard, Bank
Key Points: 

    Spritzer Clinches Dual Honors at the 2023 Putra Brand Awards

    Retrieved on: 
    Monday, March 4, 2024
    Yee, Marketing, MSA, MAA, Gold Award, Gold, Ipsos, MATRADE, Council, Dato, MDA, Accreditation, Award

    KUALA LUMPUR & TAIPING, Mar 4, 2024 - (ACN Newswire) - SPRITZER is pleased to announce that the Company is the proud recipient of two Awards at the prestigious 2023 Putra Brand Awards, Gold Award under Beverage-Non Alcoholic Category to Spritzer, and Putra Brand Personality Award under Special Awards to Founder and Managing Director Dato' Lim Kok Boon, recognising Spritzer's continuous commitment to excellence, quality and sustainability.

    Key Points: 
    • KUALA LUMPUR & TAIPING, Mar 4, 2024 - (ACN Newswire) - SPRITZER is pleased to announce that the Company is the proud recipient of two Awards at the prestigious 2023 Putra Brand Awards, Gold Award under Beverage-Non Alcoholic Category to Spritzer, and Putra Brand Personality Award under Special Awards to Founder and Managing Director Dato' Lim Kok Boon, recognising Spritzer's continuous commitment to excellence, quality and sustainability.
    • Dr. Chuah Chaw Teo, Director of Spritzer said, "We are greatly humbled by Malaysia public's recognition and trust of the Spritzer brand.
    • The Putra Brand Award is the premier brand award in Malaysia, organised by the Association of Accredited Advertising Agents Malaysia (4As) in association with the Malaysia's Most Valuable Brands (MMVB).
    • The 2023 Putra Brand Awards presented 149 winners across 24 categories, showcasing Malaysians' favourite brands in multiple categories.

    MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

    Retrieved on: 
    Sunday, March 10, 2024
    Psoriatic arthritis, ACR, Doctor of Philosophy, Adalimumab, Skin, American College, Webcast, Moonlake, HS, Patient, Psoriasis, VELA, MMSc, ARGO, MIRA, EDT, Physician, Inflammation, Safety, Prognosis, Clinical trial, Ankylosing spondylitis, TNF, IL-17A, MDA, American Academy, EMA, Medical college, FDA, Food, Steroid, Prevalence, AAD, Event, Joint, PASI, Hidradenitis suppurativa, PSA, PPP, Disease, Porokeratosis, Medicine, Pharmaceutical industry

    In addition, by week 24, over 80% and 60% of patients treated with sonelokimab achieved Psoriasis Area Severity Index (PASI) 90 and 100, respectively.

    Key Points: 
    • In addition, by week 24, over 80% and 60% of patients treated with sonelokimab achieved Psoriasis Area Severity Index (PASI) 90 and 100, respectively.
    • Treatment with sonelokimab resulted in unprecedented improvements in composite scores that reflect responses in different domains simultaneously.
    • In all composite scores, sonelokimab showed 16-29 percentage point differences to the reference adalimumab arm, comparatively higher to competitors using the same reference arm.
    • The discontinuation rate of the second part of ARGO remained low at 5%, in line with other sonelokimab trials.

    iCoreConnect Inc. Announces Expansion of Endorsement With the Michigan Dental Association

    Retrieved on: 
    Thursday, March 7, 2024
    Marketing, News, Growth, LeMat Revolver, MDA

    OCOEE, FL, March 07, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - iCoreConnect Inc. (NASDAQ: ICCT)(“iCore” or the “Company”), a leading cloud-based software and technology company focused on increasing workflow productivity and customer profitability through its enterprise and healthcare workflow platform, announced today the expansion of its collaboration with the Michigan Dental Association (“MDA”) with two new endorsements of iCore offerings.

    Key Points: 
    • This strategic collaboration marks another significant advancement in iCore’s mission to deliver innovative solutions and cutting-edge technologies tailored to the evolving needs of its customers and state association members.
    • The expansion of this collaboration allows MDA’s members to further leverage iCore’s comprehensive suite of solutions, including iCoreCodeGenius and iCoreClaims .
    • “We are thrilled to announce the expansion of our collaboration with the Michigan Dental Association, a valued and long-standing customer,” said Robert McDermott, CEO & President of iCoreConnect.
    • As a long-time, trusted partner with of the MDA, we have continuously strived to deliver high-quality products and exceptional services.

    Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

    Retrieved on: 
    Wednesday, March 6, 2024
    MRI, Therapy, SAN, Biotechnology, Skeleton, FDA, DMD, Duchenne muscular dystrophy, Conference, Patient, OLE, Cardiac muscle, Exosome, MDA, LVEF, Episcopal conference, PUL, Pharmaceutical industry

    SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company will present the positive 24-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD) at this year’s MDA Clinical and Scientific Conference which is taking place in Orlando, Florida from March 3-6, 2024.

    Key Points: 
    • SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company will present the positive 24-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD) at this year’s MDA Clinical and Scientific Conference which is taking place in Orlando, Florida from March 3-6, 2024.
    • CAP-1002 revealed clinically meaningful improvements in ameliorating cardiac function.
    • “We are pleased to be presenting our positive long-term open label extension data at this year’s MDA Conference,” said Linda Marbán, Ph.D., chief executive officer of Capricor.
    • These two-year results suggest that CAP-1002 has the potential to slow the decline of DMD progression and speaks to the potential long-term benefit for patients.

    New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

    Retrieved on: 
    Wednesday, March 6, 2024
    ALS, Aes, Research, RESPOND, BIIB, SMN2, Spinal muscular atrophy, Conference, Biogen, SMA, Safety, Biomarker, AFL, Patient, MDA, Development, Episcopal conference, Birth control

    * The Phase 4 study evaluates clinical outcomes and safety following treatment with SPINRAZA over a 2-year period in infants and toddlers with spinal muscular atrophy (SMA) who have unmet clinical needs after treatment with Zolgensma® (onasemnogene abeparvovec).

    Key Points: 
    • * The Phase 4 study evaluates clinical outcomes and safety following treatment with SPINRAZA over a 2-year period in infants and toddlers with spinal muscular atrophy (SMA) who have unmet clinical needs after treatment with Zolgensma® (onasemnogene abeparvovec).
    • The new data show that plasma neurofilament light chain (NfL) levels, an objective biomarker of axonal injury and neurodegeneration, were reduced in nearly all study participants treated with SPINRAZA.
    • These data will be presented at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 3-6, 2024).
    • “Our evolving understanding of gene therapy indicates there may be an opportunity for better outcomes,” said Crystal Proud, M.D., Pediatric Neurologist at Children’s Hospital of the King’s Daughters.

    Calian Strengthens Nuclear Capability with Acquisition of MDA Ltd. Nuclear Assets

    Retrieved on: 
    Tuesday, March 5, 2024
    Acquisition, CGY, TSX, Growth, Learning, Climate change, Bruce Power, MDA, Renewable energy

    MDA’s nuclear team will be integrated into Calian’s existing Nuclear business within its Advanced Technologies segment.

    Key Points: 
    • MDA’s nuclear team will be integrated into Calian’s existing Nuclear business within its Advanced Technologies segment.
    • “The MDA Nuclear team will add new capabilities and services to Calian’s existing nuclear business,” says Kevin Ford, CEO, Calian.
    • The addition of MDA’s nuclear team to Calian will create strong synergies, including the ability to better serve their mutual client, Bruce Power.
    • Additionally, Calian Nuclear can better support operations of existing nuclear facilities and refurbishments of the existing facilities.

    Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

    Retrieved on: 
    Tuesday, March 5, 2024
    Therapy, Myotonia, Central nervous system, Research, DYN, Dystrophin, Safety, DMPK, DMD, Exercise, Standard of care, Conference, DM1, Eteplirsen, Muscular Dystrophy Association, Fatigue, Myotonic dystrophy, Patient, Clinical trial, PMO, Male, G&A, MDA, Episcopal conference, Pharmaceutical industry

    WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the fourth quarter and full year 2023 and recent business highlights.

    Key Points: 
    • (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the fourth quarter and full year 2023 and recent business highlights.
    • Net loss: Net loss for the quarter ended December 31, 2023 was $66.6 million, or $1.09 per basic and diluted share.
    • This compares with a net loss of $38.8 million, or $0.74 per basic and diluted share, for the quarter ended December 31, 2022.
    • Net loss for the year ended December 31, 2023 was $235.9 million, or $3.95 per basic and diluted share.

    Elixirgen Therapeutics Presents Preclinical Data with Bobcat mRNATM Technology in Duchenne Muscular Dystrophy at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

    Retrieved on: 
    Monday, March 4, 2024
    Duchenne, Messenger, DMD, Duchenne muscular dystrophy, Entrepreneurship, Conference, RNA, Therapy, Muscle weakness, MDA, Atrophy, Episcopal conference, Vaccine

    BALTIMORE, March 04, 2024 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its mRNA platforms, today presented preclinical data on its proprietary Bobcat mRNATM technology in a poster presentation at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference taking place March 3-6, 2024, in Orlando, Florida. Bobcat mRNATM is designed to deliver large protein payloads (over 13 kb), and results show that a Bobcat mRNATM encoding a full-length dystrophin protein can restore muscular function in a mouse model for Duchenne muscular dystrophy (DMD).

    Key Points: 
    • Bobcat mRNATM is designed to deliver large protein payloads (over 13 kb), and results show that a Bobcat mRNATM encoding a full-length dystrophin protein can restore muscular function in a mouse model for Duchenne muscular dystrophy (DMD).
    • “We’re excited to be presenting these promising data on our novel Bobcat mRNATM technology.
    • “Our Bobcat mRNATM full-length dystrophin approach may be complementary to others currently approved or in development, or may even mitigate some of their issues.
    • We’re pleased to add the Bobcat mRNATM technology to our pipeline of RNA technologies and look forward to sharing updates in the months ahead.”

    NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences

    Retrieved on: 
    Friday, March 1, 2024
    EVP, Exercise, Hubli railway division, Conference, Phase II, SMA, Safety, Muscular Dystrophy Association, Science, Fatigue, Muscle weakness, Patient, NMD, Poster, Myasthenia gravis, Phase, MDA, Trial of the century, Congress, Pharmaceutical industry

    ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens muscle fiber excitability and is involved in regulating muscle fiber excitability during exercise.

    Key Points: 
    • ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens muscle fiber excitability and is involved in regulating muscle fiber excitability during exercise.
    • ClC-1 inhibition could be a possible mechanism to improve muscle fiber activation to address muscle weakness and fatigue in neuromuscular diseases.
    • Details of NMD Pharma’s poster presentations are below:
      The 4th Scientific International Congress on SMA is taking place in Ghent, Belgium, from 14-16 March.
    • : NMD Pharma be presenting one poster and one oral presentation at the congress.